Section Arrow
Quote
CHRO.NYSE-M
- Chromocell Therapeutics Corp
Quotes are at least 15-min delayed:2024/05/16 00:36 EDT
Last
 2.11
-0.06 (-2.76%)
Day High 
2.37 
Prev. Close
2.17 
1-M High
2.76 
Volume 
22.01K 
Bid
1.66
Ask
2.97
Day Low
1.95 
Open
2.37 
1-M Low
1.21 
Market Cap 
12.75M 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 1.88 
20-SMA 1.73 
50-SMA 2.31 
52-W High 6 
52-W Low 1.21 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-1.28/--
Enterprise Value
12.75M
Balance Sheet
Book Value Per Share
-1.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed：2024/05/16 00:36 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initialclinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.